Longeveron Inc. (LGVN)
| Market Cap | 25.89M |
| Revenue (ttm) | 1.20M |
| Net Income (ttm) | -22.70M |
| Shares Out | 29.28M |
| EPS (ttm) | -1.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 190,630 |
| Open | 0.940 |
| Previous Close | 0.900 |
| Day's Range | 0.881 - 0.940 |
| 52-Week Range | 0.475 - 1.830 |
| Beta | -0.19 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+239.33%) |
| Earnings Date | May 8, 2026 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated... [Read more]
Financial Performance
In 2025, Longeveron's revenue was $1.20 million, a decrease of -49.87% compared to the previous year's $2.39 million. Losses were -$22.70 million, -7.79% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LGVN stock is "Strong Buy" and the 12-month stock price target is $3.0.
News
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs).
Longeveron Earnings Call Transcript: Q4 2025
Secured $15M in new capital, extending cash runway into Q4 2026, while advancing pivotal HLHS and PDCM trials. Revenue fell 50% year-over-year, and net loss widened to $22.7M, but strategic partnerships and PRV opportunities could drive future growth.
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron reported financial results for the year ended December 31, 2025 and provided a business update. Results from pivotal P2 trial anticipated 3Q26.
Longeveron Braces For Q4 Results Following Recent Funding Boost
Tuesday's move higher precedes an earnings print where analysts are looking for an EPS loss of 38 cents on estimated revenue of $106,200. This revenue target represents a sharp decline from the $603,0...
Longeveron Announces Closing of Private Placement of up to $30 Million
$15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market ...
Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal
The clinical-stage biotech company, which specializes in cellular therapies for rare pediatric and aging-related conditions, secured the funding to advance its lead candidate, laromestrocel.
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal.
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant ...
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Longeveron supports the passing of the Mikaela Naylon Give Kids a Chance Act which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program.
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs,...
Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Week 2026.
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also ...
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)
Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammatio...
Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat...
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging No approv...
Longeveron Earnings Call Transcript: Q3 2025
Revenue declined 53% year-over-year due to lower demand, while net loss rose 45% as R&D and G&A expenses increased. Cash runway extends into late Q1 2026, with pivotal HLHS trial results expected in Q3 2026 and BLA filing now targeted for 2027.
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical tria...
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-rel...
Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa
Exploring potential partnerships and strategic opportunities for the Company's stem cell therapy program in Alzheimer's disease Alzheimer's disease development program with positive data in successful...
Longeveron® Announces Key Leadership Updates
Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Director...
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric...
Longeveron Earnings Call Transcript: Q2 2025
Advanced pivotal HLHS trial with BLA submission targeted for late 2026, expanded pipeline to pediatric DCM, and secured FDA alignment for key programs. Revenue declined 31% year-over-year, with increased R&D and G&A expenses; cash runway extends into Q1 2026, pending further financing.
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric...
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life...
Longeveron Announces Up To $17.5 Million Public Offering
MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life...